A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1313-1328

  Krol, Marieke ^a   Koopman, Miriam ^b   Uyl de Groot, Carin ^a   Punt, Cornelis J A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced and metastatic colon cancer; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy; Colorectal cancer; Colorectal neoplasm; Cost; Cost effectiveness; Economics; Fluoropyrimidine; Fluorouracil; Irinotecan; Monoclonal antibody; Oxaliplatin; Raltitrexed; Rectal cancer; Targeted therapy; Uracil plus tegafur

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GENERIC DRUG; IRINOTECAN; OXALIPLATIN; RALTITREXED; UFT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEALTH ECONOMICS; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; RESOURCE ALLOCATION; REVIEW; SOCIAL ASPECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WESTERN HEMISPHERE; COLORECTAL TUMOR; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; INFUSIONS, INTRAVENOUS; QUALITY OF LIFE;

EID: 34250901822     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1313     Document Type: Review

References (67)

1. VISSER O, SIESLING S, VAN DIJCK J (Eds): Incidence of cancer in the Netherlands 1999/2000. Vereniging van Integrale Kankercentra, Utrecht (2003).
2. KANKER IN NEDERLAND: Trends, prognoses en implicaties voor zorgvraag. Coebergh JWW, van de Poll-Franse LV, Alers JC (Eds), Signaleringscommissie Kanker van KWF kankerbestrijding, Amsterdam (2004).
3. YOUNG A, REA D: ABC of colorectal cancer: treatment of advanced disease. BMJ (2000) 321(7271):1278-1281.
4. PUNT CJ: New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann. Oncol. (2004) 15(10):1453-1459.
5. HADJ TAHAR A: Bevacizumab for advanced colorectal cancer. Issues Emerg. Health Technol. (2004) 63:1-4.
6. MELTZER MI: Introduction to health economics for physicians. Lancet (2001) 358(9286):993-998.
7. SCHRAG D: The price tag on progress--chemotherapy for colorectal cancer. N. Engl. J. Med. (2004) 351(4):317-319.
8. VAN DEN HOUT WB, VAN DEN BRINK M, STIGGELBOUT AM, VAN DE VELDE CJ, KIEVIT J: Cost-effectiveness analysis of colorectal cancer treatments. Eur. J. Cancer (2002) 38(7):953-963.
9. LIMAT S, BRACCO-NOLIN CH, LEGAT-FAGNONI C et al.: Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. Eur. J. Health Econ. (2006) 7(2):107-113.
10. HIEKE K, KLEEBERG UP, STAUCH M, GROTHEY A: Costs of treatment of colorectal cancer in different settings in Germany. Eur. J. Health Econ. (2004) 5(3):270-273.
11. MAROUN J, ASCHE C, ROMEYER F et al.: A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics (2003) 21(14):1039-1051.
12. WARD SE, KALTENTHALER E, COWAN J et al.: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br. J. Cancer. (2006) 95(1):27-34.
13. DRUMMOND MF, SCULPHER MS, TORRANCE GW et al.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford (2005) Ch.xv.
14. JANSMAN FG, POSTMA MJ, VAN HARTSKAMP D, WILLEMSE PH, BROUWERS JR: Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucavorin in the treatment of colorectal cancer in the Netherlands. Clin. Ther. (2004) 26(4):579-589.
15. HALE JP, COHEN DR, MAUGHAN TS, STEPHENS RJ: Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br. J. Cancer (2002) 86(11):1684-1690.
16. FOCAN C: Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer. Chronobiol. Int. (2002) 19(1):289-297.
17. NORUM J, BALTESKARD L, EDNA TH et al.: Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. J. Chemother. (2002) 14(3):301-308.
18. SCULPHER M, PALMER MK, HEYES A: Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics (2000) 17(4):361-370.
19. CUNNINGHAM D, FALK S, JACKSON D: Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br. J. Cancer (2002) 86(11):1677-1683.
20. LEVY-PIEDBOIS C, DURAND-ZALESKI I, JUHEL H et al.: Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann. Oncol. (2000) 11(2):157-161.
21. EARLE CC, KWOK A, GAZELLE GS, FUCHS CS: Two schedules of second-line irinotecan for metastatic colon carcinoma. Cancer (2004) 101(11):2533-2539.
22. HILLNER BE, SCHRAG D, SARGENT DJ, FUCHS CS, GOLDBERG RM: Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer (2005) 104(9):1871-1884.
23. POON MA, O'CONNELL MJ, MOERTEL CG et al.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. (1989) 7(10):1407-1418.
24. WEH HJ, WILKE HJ, DIERLAMM J et al.: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann. Oncol. (1994) 5(3):233-237.
25. DE GRAMONT A, BOSSET JF, MILAN C et al.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorcuracil bolus plus continuous infusion far advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. (1997) 15(2):808-815.
26. TOURNIGAND C, DE GRAMONT A, LOUVET C et al.: A simplified bimonthly regimen with leucovorin and 5 FU for metastatic colorectal cancer. Proceedings of the American Society for Clinical Oncology. California, USA (1998) 17:274. Abstr. 1052.
27. VAN CUTSEM E, TWELVES C, CASSIDY J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. (2001) 19(21):4097-4106.
28. HOFF PM, ANSARI R, BATIST G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. (2001) 19(8):2282-2292.
29. DOUILLARD JY, HOFF PM, SKILLINGS JR et al.: Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2002) 20(17):3605-3616.
30. CARMICHAEL J, POPIELA T, RADSTONE D et al.: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2002) 20(17):3617-3627.
31. MAUGHAN TS, JAMES RD, KERR DJ et al.: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 359(9317):1555-1563.
32. COCCONI G, CUNNINGHAM D, VAN CUTSEM E et al.: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J. Clin. Oncol. (1998) 16(9):2943-2952.
33. CUNNINGHAM D: Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br. J. Cancer (1998) 77(Suppl. 2):15-21.
34. WILS J: The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br. J. Cancer (1998) 77 (Suppl. 2):23-28.
35. SIMMONDS PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ (2000) 321(7260):531-535.
36. THIRION P, MICHIELS S, PIGNON JP et al.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. (2004) 22(18):3766-3775.
37. KOOPMAN M, ANTONINI NF, DOUMA J et al.: Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) Phase III study. Ann. Oncol. (2006) 17(10):1523-1528.
38. SEYMOUR M: for the NCRI Colorectal Clinical Studies Group; MRC Clin Trials Unit: fluorouracil, oxaliptatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorecral cancer (ACRC). Proceedings of the American Society for Clinical Oncology. Florida, USA (2005) 23:250s. Abstr. 3518.
39. MEYERHARDT JA, MAYER RJ: Systemic therapy for colorectal cancer. N. Engl. J. Med. (2005) 352(5):476-487.
40. PUNT CJ: Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer? Ann. Oncol. (2005) 16(6):845-846.
41. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
42. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and ceruximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
43. KABBINAVAR FF, HAMBLETON J, MASS RD et al.: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(16):3706-3712.
44. GIANTONIO B, CATALANO P, MEROPOL N et al.: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results ftom the Eastern Cooperative Oncology Group (ECOG) study E3200. Proceedings of ASCO 2005 Gastrointestinal Cancers Symposium. California, USA (2005):169. Abstr. 2.
45. CEREA G, RICOTTA R, SCHIAVETTO I et al.: Cetuximab for treatment of metastatic colorectal cancer. Ann. Oncol. (2006) 17 (Suppl. 7):vii66-vii67.
46. MAYER RJ: Two steps forward in the treatment of colorectal cancer. N. Engl. J. Med. (2004) 350(23):2406-2408.
47. BORNER M, SCHEITHAUER W, TWELVES C, MAROUN J, WILKE H: Answering patients' needs: oral alternatives to intravenous therapy. Oncologist (2001) 6(Suppl. 4):12-16.
48. LLOYD JONES M, HUMMEL S, BANSBACK N, ORR B, SEYMOUR M: A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol. Assess (2001) 5(25):1-128.
49. GOLD M, SIEGEL J, RUSSELL L, WEINSTEIN M (Ed.): Cost-effectiveness in health and medicine. Oxford University Press, Oxford (1996).
50. WOODS JR, SAYWELL RM, Jr, NYHUIS AW et al.: The learning curve and the cost of heart transplantation. Health Serv. Res. (1992) 27(2):219-238.
51. PETRELLI N, DOUGLASS HO, Jr., HERRERA L et al.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol. (1989) 7(10):1419-1426.
52. GLIMELIUS B, HOFFMAN K, OLAFSDOTTIR M et al.: Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. Eur. J. Cancer Clin. Oncol. (1989) 25(5):829-835.
53. CHEESEMAN SL, JOEL SP, CHESTER JD et al.: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br. J. Cancer (2002) 87(4):393-399.
54. MACHOVER D, GRISON X, GOLDSCHMIDT E et al.: Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a Phase I-II study. J. Natl. Cancer Inst. (1992) 84(5):321-327.
55. LOKICH JJ, AHLGREN JD, GULLO JJ, PHILIPS JA, FRYER JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol. (1989) 7(4):425-432.
56. DE GRAMONT A, TOURNIGAND C, LOUVET C et al.: [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]. Rev. Med. Interne (1997) 18(10):769-775.
57. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355(9209):1041-1047.
58. SALTZ LB, KANOWITZ J, KEMENY NE et al.: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. (1996) 14(11):2959-2967.
59. TWELVES C: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, Phase III trials. Eur. J. Cancer (2002) 38(Suppl. 2):15-20.
60. IVESON TJ, HICKISH T, SCHMITT C, VAN CUTSEM E: Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur. J. Cancer (1999) 35(13):1796-1804.
61. FUCHS CS, MOORE MR, HARKER G et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. (2003) 21(5):807-814.
62. ROUGIER P, VAN CUTSEM E, BAJETTA E et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1407-1412.
63. LEVI F, ZIDANI R, MISSET JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet (1997) 350(9079):681-686.
64. LEVI FA, ZIDANI R, VANNETZEL JM et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl Cancer Inst. (1994) 86(21):1608-1617.
65. LEVI F, ZIDANI R, LLORY J et al.: Final efficacy update at 7 years of flat vs chronomodulated infusion (Chrono) of oxaliplatin, 5-fluorouracil and leucovorin as first line treatment of metastatic colorectal cancer. Proceedings of the Amencan Society for Clinical Oncology. Illinois, USA (2000):19. Abstr. 936.
66. GOLDBERG RM, SARGENT DJ, MORTON RF et al.: Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J. Clin. Oncol. (2002) 20(23):4591-4596.
67. GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22(1):23-30.